Insulin's High Cost Leads To Lethal Rationing
(Source: NPR Health and Science)
Source: NPR Health and Science - September 1, 2018 Category: Consumer Health News Authors: Bram Sable-Smith Source Type: news

Insulin boosts the immune system to fight infection
Research, published inCell Metabolism, reveals a pathway connecting insulin signalling and the activity of T cells to boost immune response.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 31, 2018 Category: Endocrinology Source Type: news

Amazonian fruit improves insulin sensitivity
Mice fed an extract of a fruit which only grows in the amazon, show improved glucose tolerance and insulin sensitivity, according to research published inGut. Science Alert (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 31, 2018 Category: Endocrinology Source Type: news

Immune cell checkpoints implicated in type-1 diabetes
Research, published inFrontiers in Immunology, suggests that specific immune cells, which fail to respond to checkpoint molecules, attack insulin-producing cells in a model of type-1 diabetes.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 30, 2018 Category: Endocrinology Source Type: news

Insulin gives an extra boost to the immune system
(University Health Network) The role of insulin as a boost to the immune system to improve its ability to fight infection has been detailed for the first time by Toronto General Hospital Research Institute scientists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2018 Category: International Medicine & Public Health Source Type: news

BD inks UAE insulin pen distro deal with Julphar
Pharmaceutical manufacturer Julphar said yesterday it inked a deal with BD (NYSE: BDX) to supply disposable insulin pens to the United Arab Emirates. Through the deal, individuals will be able to purchase BD’s Vystra disposable pens featuring Julphar’s human insulin formulations, including its Jusline R, Jusline N and Jusline 30/70. The same system is slated to be available for future insulin analogues which are still under development, Julphar said. Read the whole story on our sister site, Drug Delivery Business News The post BD inks UAE insulin pen distro deal with Julphar appeared first on MassDevi...
Source: Mass Device - August 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Diabetes Distribution bectondickinson julphar Source Type: news

Snacking on almonds might compensate for skipping breakfast
EXCLUSIVE Researchers from the University of California, Merced, also found that snacking on almonds at 11am after missing breakfast lowers a student's insulin resistance. (Source: the Mail online | Health)
Source: the Mail online | Health - August 24, 2018 Category: Consumer Health News Source Type: news

Evidation, Tidepool pool resources on diabetes behavior study
Photo by rawpixel on Unsplash Health measurement company Evidation Health and diabetes data firm Tidepool have launched a research program to study real-world data from people with type 1 diabetes. The T1D Sleep Pilot will develop insights from data generated by continuous glucose monitors and insulin pumps, in addition to sleep and activity trackers from smartphones and other connected sensors. The observational study will explore links between nocturnal hypoglycemia, next-day behavior, sleep patterns, and heart rates in order to contribute to ongoing research on how everyday behavior data and diabetes complicat...
Source: Mass Device - August 24, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Diabetes Research & Development Evidation Health Tidepool Source Type: news

Vitamin D, Glycemic Control, and Insulin Resistance Vitamin D, Glycemic Control, and Insulin Resistance
Vitamin D supplementation may help prevent the development of type 2 diabetes among patients at risk by improving glycemic measures and insulin sensitivity.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

DexCom Shines in Busy M & amp;A Season with TypeZero Buy
It’s not too often that DexCom makes headlines for making an acquisition. Usually, DexCom is the preferred partner to firms looking to leverage the San Diego, CA-based company’s expertise in the continuous glucose monitoring market. However, DexCom said it is going to acquire TypeZero Technologies, for an undisclosed sum. Charlottesville, VA-based TypeZero’s offering includes the inControl diabetes management system, designed to provide personalized diabetes management solutions including technology to automatically adjust and regulate insulin delivery. â€...
Source: MDDI - August 23, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Valeritas launches V-Go insulin delivery device in Australia
Valeritas (NSDQ:VLRX) said today that it launched its V-Go wearable insulin delivery device in Australia. The company inked an exclusive distribution agreement in Australia with AMSL Diabetes earlier this year. Get the full story at our sister site, Drug Delivery Business News. The post Valeritas launches V-Go insulin delivery device in Australia appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Valeritas Source Type: news

Dexcom acquires diabetes management tech with TypeZero purchase
Dexcom (NSDQ:DXCM) said this week that it acquired TypeZero Technologies and its personalized diabetes management solutions. The financial details of the transaction were not disclosed. Dexcom plans to support the first commercial launch of an automated insulin delivery system using TypeZero’s inControl algorithm next year. Get the full story at our sister site, Drug Delivery Business News. The post Dexcom acquires diabetes management tech with TypeZero purchase appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Dexcom TypeZero Technologies Source Type: news

A sugar that increases insulin sensitivity
The sugar trehalose boosts insulin sensitivity lowering the chance of developing diabetes, according to a study published inJCI Insight.MedicalXpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 23, 2018 Category: Endocrinology Source Type: news

Report: UK startup hopes to communicate directly with the nervous system
Cambridge University spin-out Cambridge Bio-Augmentation Systems and tech company Nvidia are partnering to work on a system that they hope will allow devices to directly communicate with the human central nervous system, according to a new Forbes report. CBAS is developing neural interfaces they say will allow external devices to communicate directly with the central nervous system, hoping that if they are able to talk to the system, they could manage chronic diseases “at the root,” according to the report. “We’re building what is essentially a USB port to allow communication with the nervous system...
Source: Mass Device - August 22, 2018 Category: Medical Devices Authors: Fink Densford Tags: Research & Development cambridgebioaugmentationsystems Source Type: news

Eating a Christmas dinner might diagnose diabetes earlier than the standard glucose drink
Researchers from  Cambridge University found that giving mice a high-fat, high-calorie meal detects insulin resistance more accurately than sugary drink given to suspected diabetics. (Source: the Mail online | Health)
Source: the Mail online | Health - August 22, 2018 Category: Consumer Health News Source Type: news

New type 1 diabetes therapy shows promise for long-term reversal in both humans, dogs
(Purdue University) A collagen formulation mixed with pancreatic cells, developed by Purdue University researchers in collaboration with the Indiana University School of Medicine, is the first minimally invasive therapy to successfully reverse Type 1 diabetes within 24 hours and maintain insulin independence for at least 90 days, a pre-clinical animal study shows. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 21, 2018 Category: International Medicine & Public Health Source Type: news

Xeris Pharmaceuticals kicks off dual-hormone artificial pancreas trial
Xeris Pharmaceuticals (NSDQ:XERS) said last week that it launched a Phase I trial of its ready-to-use liquid glucagon in a closed-loop, dual-hormone artificial pancreas system. Automated insulin delivery systems represent the latest advancement in diabetes management. But these technologies fall short of performing the tasks of a human pancreas – they deliver insulin, but they can’t co-deliver glucagon. Traditional dry-powder glucagon formulations must be used immediately, according to Xeris, or else they begin to degrade. Get the full story at our sister site, Drug Delivery Business News. The post Xeris P...
Source: Mass Device - August 20, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat xerispharmaceuticals Source Type: news

Tandem launches insulin pump with predictive low glucose suspend feature in US
Tandem Diabetes Care (NSDQ:TNDM) last week launched its t:slim X2 insulin pump with Basal-IQ technology in the U.S. The company’s latest pump includes a predictive low glucose suspend feature designed to reduce the frequency and duration of hypoglycemia. Get the full story at our sister site, Drug Delivery Business News. The post Tandem launches insulin pump with predictive low glucose suspend feature in US appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 20, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat tandemdiabetes Source Type: news

Building a Better Insulin Infusion System
Capillary Biomedical is looking to develop a safer more reliable and accurate insulin infusion device. The Irvine, CA-based company has closed on $2.9 million in a series seed financing to help get its SteadiSet infusion set on the market. The Series Seed financing involved several Angel groups, including Tech Coast Angels, New York Angels, HBS Alumni Angels of New York, Pasadena Angels and the Mass Medical Angels, making the financing one of the broadest and most successful syndications among Angel investor groups. Other investors included the ACE Fund, PA Fund and NYA Fund. Financing proceeds will be used for clinical tr...
Source: MDDI - August 18, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Tubing Source Type: news

Expanding Glucagon Access and Use in the Prehospital Setting
In cases of severe hypoglycemia, an intramuscular injection of glucagon remains the preferred method of treatment.1 Unfortunately, in many states regulatory polices prevent EMT-Basics from being able to administer or carry glucagon, which makes treating such patients experiencing severe hypoglycemia with loss of consciousness far more complicated  and slower than necessary. In addition to the unavailability of glucagon, many EMTs aren’t permitted to perform blood glucose testing (i.e., fingersticks), which makes the identification and treatment of hypoglycemia even more challenging. Severe hypoglycemic events re...
Source: JEMS Patient Care - August 17, 2018 Category: Emergency Medicine Authors: Peter Kahn, MD, MPH, NREMT Tags: Exclusive Articles Patient Care Source Type: news

Expanding Glucagon Access and Use in the Prehospital Setting
In cases of severe hypoglycemia, an intramuscular injection of glucagon remains the preferred method of treatment.1 Unfortunately, in many states regulatory polices prevent EMT-Basics from being able to administer or carry glucagon, which makes treating such patients experiencing severe hypoglycemia with loss of consciousness far more complicated  and slower than necessary. In addition to the unavailability of glucagon, many EMTs aren’t permitted to perform blood glucose testing (i.e., fingersticks), which makes the identification and treatment of hypoglycemia even more challenging. Severe hypoglycemic events re...
Source: JEMS Special Topics - August 17, 2018 Category: Emergency Medicine Authors: Peter Kahn, MD, MPH, NREMT Tags: Exclusive Articles Patient Care Source Type: news

Voluntis launches upgraded insulin dosing therapeutic
Voluntis this week launched an upgraded version of Insulia, its digital therapeutic designed to give automated basal insulin dose recommendations and coaching messages for people with Type 2 diabetes. The company touted that its upgraded version of Insulia improves user experience and offers Spanish programming. Get the full story at our sister site, Drug Delivery Business News. The post Voluntis launches upgraded insulin dosing therapeutic appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Voluntis Source Type: news

Is Oatmeal Healthy? Here ’s What the Experts Say
Oatmeal is a near-universally beloved breakfast. While it has historically been enjoyed across Europe, Russia and the U.S., oatmeal is rapidly gaining popularity in developing countries because of its affordability and its perceived health properties. But is oatmeal really good for you? To answer that question, it’s first important to differentiate among all the different types of oatmeal. There’s steel-cut and rolled, quick-cooking and instant. But all of these terms refer to different methods of preparing hulled oats for cooking. “You can’t eat an unprocessed oat straight from the field,” sa...
Source: TIME: Health - August 15, 2018 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Diet/Nutrition healthytime Source Type: news

Is One Basal Insulin Just Like Another? Is One Basal Insulin Just Like Another?
A new review suggests that we may be fooling ourselves by rating one high-priced insulin over another.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2018 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Nemours finishes historic children's diabetes research
As part of a research project conducted by four institutions across the nation, one Jacksonville hospital is taking part in the next big break in type 1 diabetes treatment. Researchers at Nemours Children's Specialty Care on the Southbank of the St. Johns River recently completed a two-week trial of a device that could transform the lives of those living with the disease. The device, called iLet, mimics a pancreas by automatically dosing insulin, glucagon or a comb ination of the two as needed.… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2018 Category: Pharmaceuticals Authors: Allison Colburn Source Type: news

Load up on omega-3 and omega-6 fatty acids to prevent obesity and improve your insulin resistance
(Natural News) Not all fats are bad. A group of essential fats from plants is downright important in maintaining and improving the healthy functions of your body. A newly-published Canadian study identified alpha-linolenic acid (ALA) and linoleic acid (LA) as the omega fatty acids that reduce the risks of obesity and improve your resistance to high levels... (Source: NaturalNews.com)
Source: NaturalNews.com - August 15, 2018 Category: Consumer Health News Source Type: news

Capillary Biomedical closes $2.9 million seed round
Capillary Biomedical Inc. has raised $2.9 million in a seed funding that will help it bring its diabetes management technology to market. The round was led by the Cove Fund with participation by a syndicate of Angel Groups and accredited investors. Irvine, California-based Capillary Biomedical said it plans to use the funds for clinical studies to support regulatory clearance and preparation for commercial launch in 2019. CapBio i s developing a novel infusion set for use with insulin pumps for… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 14, 2018 Category: Biotechnology Authors: I-Chun Chen Source Type: news

Capillary Biomedical closes $2.9 million seed round
Capillary Biomedical Inc. has raised $2.9 million in a seed funding that will help it bring its diabetes management technology to market. The round was led by the Cove Fund with participation by a syndicate of Angel Groups and accredited investors. Irvine, California-based Capillary Biomedical said it plans to use the funds for clinical studies to support regulatory clearance and preparation for commercial launch in 2019. CapBio i s developing a novel infusion set for use with insulin pumps for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 14, 2018 Category: Pharmaceuticals Authors: I-Chun Chen Source Type: news

Capillary Biomedical raises $3m to support insulin infusion tech
Capillary Biomedical said today that it raised $2.9 million in a seed funding round to support regulatory filings and the launch of its insulin infusion technology. The company is gearing up for clinical trials to support a 510(k) filing and hopes to bring its SteadiSet infusion set to the market in 2019. Get the full story at our sister site, Drug Delivery Business News. The post Capillary Biomedical raises $3m to support insulin infusion tech appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup Pharmaceuticals capillarybiomedical Source Type: news

Healthy fat cells uncouple obesity from diabetes
(Baylor College of Medicine) Researchers have identified possible ways to uncouple obesity from co-morbidities such as heart disease and insulin resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2018 Category: International Medicine & Public Health Source Type: news

The balloon to treat women's health issues
Called Revita, the device is already used for type 2 diabetes because the burning process, ablation, burns off cells which have become resistant to insulin. (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2018 Category: Consumer Health News Source Type: news

GI Dynamics wins FDA nod for pivotal US EndoBarrier trial
GI Dynamics (ASX:GID) said today it won FDA investigational device exemption approval to launch a pivotal trial of its EndoBarrier device designed for treating patients with type 2 diabetes and obesity, pending Institutional Review Board approval. The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract to treat type 2 diabetes and obesity, the Lexington, Mass.-based company said. The approval is a boon for the company, which has faced a number of hurdles with its device over the past few years, inclu...
Source: Mass Device - August 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Diabetes Food & Drug Administration (FDA) Regulatory/Compliance Weight loss GI Dynamics Source Type: news

JDRF Partnership Will Help Fayetteville Company Develop Insulin Pump
SFC Fluidics of Fayetteville is closer to bringing its first product, a wearable insulin pump, to market, thanks to its partnership with JDRF. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - August 13, 2018 Category: American Health Source Type: news

Studies Unable to Reproduce Results of Two Diabetes Papers
The original work found that an anti-malaria drug or the neurotransmitter GABA could increase the number of insulin-producing pancreatic cells in mice. (Source: The Scientist)
Source: The Scientist - August 10, 2018 Category: Science Tags: News & Opinion Source Type: news

How Insulet ’s CEO plans to create a billion-dollar business
When Pat Sullivan joined Insulet (NSDQ:PODD) in 2014, the Billerica, Mass.-based company was reeling in roughly $300 million in revenue selling its Omnipod tubless insulin delivery system. Sullivan, a veteran of the medtech industry, saw a path to creating a billion-dollar company and it centered around the concept of making life easier for people with diabetes. “I have an attraction to bringing new and innovative technology to market and I was totally enamored with the Omnipod. I understood why this product should be the standard of care in insulin delivery and I’ve been working for the last four yea...
Source: Mass Device - August 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Insulet Source Type: news

Report: ICS-CERT tags 2 Medtronic devices with cybersecurity vulnerabilities
The US Dept. of Homeland Security’s Industrial Control Systems Computer Emergency Response Team this week flagged two Medtronic (NYSE:MDT) devices for cybersecurity vulnerabilities that could allow attackers to obtain sensitive information, according to a HealthITSecurity report. The Fridley, Minn.-based medtech giant’s MyCareLink patient monitor and MiniMed Paradigm insulin pump and remote controller were specifically identified by the group, according to the report. ICS-Cert said that the MyCareLink patient monitor insufficiently verifies data authenticity and allows passwords to be stored in a reco...
Source: Mass Device - August 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Software / IT Medtronic Source Type: news

Medical News Today: Keto diet: Scientists find link to diabetes risk
A mouse study finds that the liver becomes insulin resistant in the early stages of a ketogenic diet. Insulin resistance raises risk of type 2 diabetes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 9, 2018 Category: Consumer Health News Tags: Nutrition / Diet Source Type: news

Technique uses nanoparticles to deliver oral medication
Researchers believe they have figured out a way to use nanoparticles as a way to deliver oral medication, including an insulin pill to control diabetes. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 8, 2018 Category: Consumer Health News Source Type: news

Education on insulin use is lacking in doctors
According to research, published inBMC Family Practice, primary care physicians lack appropriate knowledge on the correct use of insulin to treat type-2 diabetes.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 8, 2018 Category: Endocrinology Source Type: news

Hormones in a bottle that help you stay slim by suppressing your appetite  
Tests suggest that regularly spraying small doses of insulin into the nostrils can suppress the appetite, potentially triggering significant weight loss. (Source: the Mail online | Health)
Source: the Mail online | Health - August 6, 2018 Category: Consumer Health News Source Type: news

Valeritas lands distro deal in Czech Republic, Slovakia
Valeritas (NSDQ:VLRX) said today that it inked an expanded deal with Med Trust, its distribution partner in Austria and Germany, to promote and sell the V-Go wearable insulin delivery device in the Czech Republic and Slovakia. According to the terms of the deal, Valeritas will be responsible for product development, regulatory approval, quality management and manufacturing the device while Med Trust will take over the sales, marketing and distribution activities. Get the full story at our sister site, Drug Delivery Business News. The post Valeritas lands distro deal in Czech Republic, Slovakia appeared ...
Source: Mass Device - August 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Valeritas Source Type: news

Muscle and fat composition is affected by hormone levels in euthyroid adults
A study, published inClinical Endocrinology, reports that higher levels of thyroid hormone are associated with reduced skeletal muscle mass and insulin resistance.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 6, 2018 Category: Endocrinology Source Type: news

Insulin resistance goes undetected in patients with Parkinson's disease
According to a study, published in theJournal of Parkinson's Disease, insulin resistance is often undetected in Parkinson's disease patients, especially in overweight individuals.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 6, 2018 Category: Endocrinology Source Type: news

Diabetes type 2: This fatty food could help REVERSE your blood sugar problems
DIABETES type 2 happens when there are problems with the hormone insulin. People more at risk tend to be overweight and exercise rarely. However, it may be possible to reduce your risk of blood sugar problems by eating this food. (Source: Daily Express - Health)
Source: Daily Express - Health - August 4, 2018 Category: Consumer Health News Source Type: news

Increasing Cost of Insulin Has Serious Health Consequences
FRIDAY, Aug. 3, 2018 -- The increasing cost of insulin is potentially exposing those with diabetes to serious health consequences, according to an American Diabetes Association statement published in the June issue of Diabetes Care. Noting that the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 3, 2018 Category: Pharmaceuticals Source Type: news

Novartis and Sanofi Stockpile Meds in Preparation for Brexit
If the UK leaves the EU in March without a deal, transport of insulin and other essential drugs could be delayed. (Source: The Scientist)
Source: The Scientist - August 3, 2018 Category: Science Tags: News & Opinion Source Type: news

V-Go Shown to Have Improved Benefit for Insulin Patients
This study demonstrated that patients treated by Advanced Practitioners experienced improved A1c levels while lowering insulin total daily dose (TDD) after switching to V-Go from MDI of insulin. Patients in this study were evaluated after a mean duration of three and seven months. At three months, the mean change in A1c was -1.1% from the mean baseline of 9.1%, and mean insulin TDD decreased to 58 units per day from a mean baseline of 87 units per day. At seven months, the mean change in A1c was also -1.1%, while the mean insulin TDD was 61 units per day. Change in the mean weight was less than 1 kg at both time points. &a...
Source: MDDI - August 3, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Crash diet can reverse Type 2 diabetes by rebooting insulin producing cells, study finds
The new findings come from a study of 298 people led by the universities of Newcastle and Glasgow, which found 46% on a crash diet reversed their diabetes replacing food with shakes and soups. (Source: the Mail online | Health)
Source: the Mail online | Health - August 3, 2018 Category: Consumer Health News Source Type: news

Spiking Insulin Costs Put Patients in Brutal Bind Spiking Insulin Costs Put Patients in Brutal Bind
Insulin prices have skyrocketed in recent years, on average tripling between 2002 and 2013. One popular brand, NovoLog, increased in list price by 353% from 2001 to 2016.WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 2, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Valeritas touts use of V-Go device compared to insulin injections
Valeritas (NSDQ:VLRX) touted data today from an analysis showing that insulin-dependent people with Type 2 diabetes benefited from using the company’s wearable V-Go insulin delivery device. The study featured people who previously treated their diabetes using multiple daily injections of insulin. After switching to the V-Go device under the care of advanced practitioners, participants were monitored and evaluated at the three- and seventh-month mark. Get the full story at our sister site, Drug Delivery Business News. The post Valeritas touts use of V-Go device compared to insulin injections appeared first on Mas...
Source: Mass Device - August 2, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Valeritas Source Type: news